Investment Research & Advisory Group Inc. Purchases 177 Shares of Danaher Co. (NYSE:DHR)

Investment Research & Advisory Group Inc. raised its position in shares of Danaher Co. (NYSE:DHR) by 3.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,338 shares of the conglomerate’s stock after buying an additional 177 shares during the quarter. Investment Research & Advisory Group Inc.’s holdings in Danaher were worth $1,225,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Decker Retirement Planning Inc. purchased a new position in shares of Danaher in the fourth quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new position in shares of Danaher in the 3rd quarter worth $39,000. MidAtlantic Capital Management Inc. purchased a new stake in shares of Danaher during the 3rd quarter valued at about $40,000. FSA Wealth Management LLC bought a new position in shares of Danaher in the 3rd quarter valued at about $50,000. Finally, Darwin Wealth Management LLC purchased a new position in Danaher in the third quarter worth about $55,000. Institutional investors own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on DHR shares. Raymond James lowered their price objective on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a research note on Tuesday, January 21st. Evercore ISI boosted their price objective on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. Bank of America upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a report on Friday, December 13th. Citigroup cut their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Royal Bank of Canada dropped their target price on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Six equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Trading Up 0.1 %

Shares of NYSE:DHR opened at $245.95 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $177.65 billion, a PE ratio of 46.94, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a 12-month low of $225.42 and a 12-month high of $281.70. The business’s fifty day simple moving average is $235.33 and its 200-day simple moving average is $253.45.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio is presently 20.61%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.